For more than a year, expert teams at Mass General Brigham (MGB) have been at work developing and beginning the implementation of a single vision and strategy for Mass General Brigham Cancer. This strategy is focused on expanding MGB Cancer’s clinical and academic resources by investing in the clinicians, researchers and staff who will make that vision a reality.
To enable this growth, MGB is building significant capacity for present and future cancer faculty, teams and technology throughout the system and with existing and new partners, with a goal of expanding access to high-quality care for communities throughout the region.
Today, Anne Klibanski, MD, president and CEO of MGB, announced plans to invest approximately $400 million over the next four years to build outpatient capacity on the Brigham and Women’s Hospital (BWH) and other MGB campuses, recruit top oncologists, implement digital pathology and enhance support staffing.
“In the last year, we have made significant progress toward our vision for Mass General Brigham Cancer,” said O’Neil Britton, MD, chief integration officer for MGB. “The investments announced today arose from our strategic planning process and enable us to take deliberate steps to execute on our priorities.”
Three floors of the Hale Building at BWH and one floor of Brigham and Women’s Faulkner Hospital are being extensively renovated to provide world-class outpatient clinical space for MGB Cancer. This space will support MGB Cancer’s integrated care model, with the transition planning starting immediately.
The combined approach across the Massachusetts General Hospital and Brigham and Women’s Hospital campuses, and across the health system, enables MGB Cancer to be fully operational using its own space and resources before the conclusion of the current agreement with Dana-Farber Cancer Institute in 2028.
The Hale Building, which opened in 2016, is one of the most technologically advanced patient care and research facilities in the country, seamlessly integrating clinical care with cutting-edge research. The investment announced today will create cancer capability within the Hale Building and facilitate collaboration across expert teams (such as specialists in the MGB Neuroscience Institute, who are co-located in the Hale Building).
“This space enhances our capabilities across the Brigham campuses and provides world-class support for our clinicians, researchers, trainees and staff,” said David F. M. Brown, MD, president of academic medical centers for MGB.
Importantly, these plans complement the new Herb Chambers Tower at the Phillip and Susan Ragon Building, which is currently under construction and scheduled to open in 2027, and which will be heavily focused on cancer, along with plans underway to add significant new exam room and infusion capacity at Mass General Brigham Healthcare Center (Waltham).
“Our goal is to immediately begin to execute on our cancer strategy and provide space for both our existing and new cancer teams to work, perform research and care for patients,” said Kevin Giordano, MBA, senior vice president of operations for MGB, who oversees the operations of MGB Cancer.
“Bringing the unmatched resources of our two great academic medical centers and our entire system together, we are building a brighter future for cancer care at Mass General Brigham,” Dr. Klibanski said in today’s announcement. “Together, we truly are one against cancer.”
